News & Insights

Pharmaceutical manufacturing runs on energy the way it runs on water and clean air. The processes that make a product safe are the same ones that make these facilities some of the most energy-intensive industrial sites in operation. That’s the core tension in any decarbonization effort here: the biggest energy loads aren’t waste, they’re the job.

The industry’s footprint bears this out. My Green Lab’s Carbon Impact of Biotech & Pharma report puts the sector at 4.4% of total global emissions. Most of that sits in the supply chain, outside any single facility’s direct control. But the emissions a facility does control, Scopes 1 and 2 from energy use on site, are both substantial and genuinely movable, and the largest companies are proving it: they’ve posted a 10% decline in Scope 1 and 2 emissions as operational practice has caught up with their targets. That’s the territory where facility and engineering decisions actually move the number.

For facility and engineering leaders, the question isn’t whether to decarbonize. Corporate targets and investor expectations have settled that. The question is how to cut emissions without putting product quality, regulatory compliance, or operational continuity at risk. This article covers the constraints that make pharma different, the technical levers that pay off, the specific problem of aging facilities, and how to sequence the work so it survives a capital review.

Why pharma decarbonization doesn’t follow the commercial playbook

Most decarbonization guidance is written for offices, warehouses, and general industrial buildings. Pharma facilities break those assumptions in four places.

Environmental control is a product requirement, not a comfort setting. Biologics and many other products need tight control of temperature, humidity, and pressurization, and that control has to hold from the cleanroom through cold chain distribution. HVAC is typically the single largest energy consumer in these facilities. It can’t be dialed back the way it can in a commercial building, because the load exists to protect the product.

Ultra-pure water is expensive to make, and there’s no cheap substitute. Water for injection (WFI) goes into products administered directly to patients, and producing it through distillation and advanced filtration is energy-intensive by design. Newer membrane and lower-temperature purification methods are gaining ground, but for most injectable and IV products the energy needs/requirements of purity remains fixed.

Steam ties everything together, which makes fuel-switching a redesign. A single steam system often feeds sterilization, heating, and water purification at once. Electric boilers and heat pump systems can replace fossil-fuel boilers, but rarely as a like-for-like swap. The distribution infrastructure usually has to be re-engineered to match the output and efficiency profile of the new equipment. That’s a capital project with a validation trail attached.

Every change is a regulatory event. Switching an energy source or upgrading equipment triggers validation and testing to confirm that safety and efficacy are unaffected. This oversight is essential, and it also slows adoption. It’s why “if it isn’t broken, don’t fix it” is a defensible position for a plant manager, not a sign of low ambition.

There’s a fifth factor that sits mostly outside the fence line: supply chain, or Scope 3, emissions. Raw materials, active pharmaceutical ingredients, excipients, transportation, and packaging all carry embedded carbon that a facility doesn’t directly control. It’s the largest share of most companies’ footprints and the hardest to move, which is exactly why operational emissions are worth attacking hard. They’re the part you can actually reach.

The engineering levers that pay off

The technical options are well understood. What separates a plan that works from one that stalls is knowing where each lever fits and where it doesn’t.

Heat pumps and geothermal, sized and sited honestly. Air-source heat pumps are increasingly considered for central plant design, while geothermal strategies use closed-loop borefields or open-loop groundwater systems to provide a more stable source and sink for heating and cooling. Geothermal can be highly efficient for campuses with continuous, simultaneous loads, but feasibility depends on land, geology, hydrogeology, drilling access, and existing infrastructure. Air-source systems derate in cold climates and may need backup capacity. Both work when matched to actual site conditions and load profiles; most disappointments trace back to sizing and siting rather than the technology.

Air recirculation, where a lot of savings sit unclaimed. Facilities designed around 100% outside air are expensive to condition and often more conservative than the cleanroom classification requires. Improvements in filtration, dehumidification, distribution, and controls make it possible to lower air change rates while holding particulate and microbial standards. This is one of the few high-value moves that needs no new capital equipment, just better control logic and, in some cases, a requalification study.

Waste heat recovery, the fast payback nobody argues with. Sterilization and WFI production generate high-grade heat that’s frequently vented. Capturing it to preheat process water or feed low-temperature heating loops delivers strong returns and doesn’t touch the primary process, which keeps the validation conversation manageable.

Control systems, the cheapest lever in the building. Adjusting chiller setpoints, shutting down idle compressors in compressed air systems, and scheduling HVAC around real production and occupancy patterns cut energy waste with little or no capital outlay. The operational data these systems produce is also what makes every larger decision defensible when it reaches a validation team.

Electrification, immediate emissions return on a long-dated payback. Converting gas-fired boilers to electric or hybrid systems carries an upfront cost with a long dollar-for-dollar ROI, but the emissions reduction lands the day the equipment goes live. Distribution fleets follow the same logic and are often an easier place to start, since they sit entirely outside GMP-validated systems.

On-site generation and PPAs for Scope 2. On-site solar, small wind turbines where geography allows, and power purchase agreements with renewable providers cut the emissions tied to purchased electricity without altering the manufacturing process. This is usually the least disruptive lever and the one finance teams find easiest to model.

The aging facility problem

A large share of pharmaceutical production still runs in plants built decades ago, and these sites carry a specific set of decarbonization challenges that new construction doesn’t.

The infrastructure is often oversized and inflexible. Older facilities were commonly designed with generous safety margins, constant-volume air handling, and single-speed equipment, all of which lock in energy consumption regardless of actual demand.

Documentation is another obstacle. As-built drawings may be incomplete or out of date after years of modifications, which means the first real cost of any project is understanding what’s actually installed before anything can be changed.

Space is a constraint. Retrofitting heat pumps, heat recovery equipment, or additional electrical capacity assumes room in the mechanical spaces and electrical service that older sites frequently don’t have. And the validation burden is heavier, because touching systems in a facility that’s been in continuous GMP production for years risks disrupting processes that regulators have signed off on and that generate revenue every day they run.

The infrastructure constraint may extend beyond the facility itself. One pharmaceutical client pursuing decarbonization requested a larger electrical service from its utility, only to learn that the upgrade would require broader improvements to the surrounding distribution system. The resulting cost made the project prohibitively expensive, showing how grid capacity can limit electrification even when the facility is ready to move forward.

None of this makes aging facilities a lost cause. In several respects, they offer more opportunity than a modern plant, because the baseline is so inefficient that the easy wins are large.

The path that works starts with the low-disruption levers. Recommissioning and control system upgrades routinely surface significant savings in older facilities precisely because the original design was conservative and the equipment has drifted out of tune over years of operation. Air change rate reduction is often available in older cleanrooms that were designed to standards more stringent than current guidance requires, and it can be captured without physical construction. Waste heat recovery can frequently be added to existing steam and purification systems without disturbing the core process. From there, deeper interventions like electrification and central plant replacement can be timed to coincide with equipment reaching end of life, so the carbon upgrade rides along with a capital replacement that was going to happen anyway rather than arriving as a separate, harder-to-justify expense.

The strategic move with an aging facility is to stop treating decarbonization as a standalone project and start folding it into the maintenance, replacement, and capacity decisions the site is already making. That reframing turns the age of the building from a liability into a schedule of opportunities.

Sequencing the work so it survives a capital review

A phased approach beats a single grand commitment, because each phase carries a different capital ask and a different validation burden, and each can be funded and executed on its own timeline.

Start with measurement. Establish an emissions baseline across HVAC, clean utilities, steam, process cooling, and cold chain, using sensors and meters to get real consumption data rather than nameplate estimates. Everything downstream depends on knowing where the energy actually goes.

Then move through the levers in rough order of disruption. Controls, setpoints, and air change rates first, since they’re low capital and fast payback. Retrofits like waste heat recovery and equipment upgrades next, as normal facilities projects with a manageable validation scope. Then the deeper transformations, fuel switching, central plant electrification, and on-site generation, sequenced against the capital plan and, wherever possible, against equipment already due for replacement.

Two habits make the difference in practice: break ambitious corporate targets into steps small enough to measure and defend individually, so momentum builds on visible wins instead of stalling on a single large program. And treat the operational data from your control systems as the foundation for every business case, because in a regulated environment, the ability to prove an intervention won’t compromise product quality is what gets it approved.

Where to start

Measure, then tune what you already have, then retrofit, then transform. The order matters because it front-loads the lower dollar, low-risk savings that build the credibility and the data you’ll need to fund the expensive work later.

Peer networks are worth the time, particularly ISPE for benchmarking against facilities that share your constraints. And an engineering partner that has done this work in validated environments can compress the timeline considerably, because the hardest part of pharma decarbonization isn’t picking technologies. It’s knowing which ones will clear validation in your specific facility, and in what order.

Want to talk specifically about your context? Reach out to one of our contributors below or reach out to [email protected].

For media inquiries on this article, reach out to [email protected].